Sugi Predict

Sugi Predict / Compounds / SCHEMBL9989117

SCHEMBL9989117

SCHEMBL9989117

CS(=O)(=O)Cc1ccc(Br)cn1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MBOAT4 Q96T53 1/20 0.37
▸ GRM2 Q14416 1/20 0.35
▸ RAB9A P51151 3/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KCNH2 Q12809 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ PLCG1 P19174 1/20 0.32
▸ SYK P43405 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16180689 0.85 GBA1 (0.41) GBA1ALDH1A1KDM4EMBOAT4GRM2
SCHEMBL15612500 0.81 GBA1 (0.41) GBA1ALDH1A1KDM4EMBOAT4GRM2
SCHEMBL28895225 0.81 GBA1 (0.39) GBA1ALDH1A1KDM4EMBOAT4GRM2
SCHEMBL1662137 0.80 GBA1 (0.40) GBA1ALDH1A1KDM4EMBOAT4GRM2
SCHEMBL31419110 0.80 GBA1 (0.40) GBA1ALDH1A1KDM4EMBOAT4GRM2
SCHEMBL14671606 0.78 NOS3 (0.43) ALDH1A1KDM4ERAB9AKCNH2ATM
SCHEMBL14659469 0.78 CA12 (0.47) MBOAT4LMNAKCNH2ATMTSHR
SCHEMBL30648743 0.78 CA12 (0.47) MBOAT4LMNAKCNH2ATMTSHR
SCHEMBL15612266 0.78 GBA1 (0.37) GBA1ALDH1A1KDM4EMBOAT4GRM2
SCHEMBL16188556 0.77 GBA1 (0.38) GBA1ALDH1A1KDM4EMBOAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-11912721-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2024-02-27 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20130244993-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-09-19 — — US disclosed
US-20130244993-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-09-19 — — US disclosed
EP-2582698-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE Vitae Pharmaceuticals, Inc. (US) 2013-04-24 — — EP disclosed
US-20130029962-A1 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2013-01-31 — — US disclosed
WO-2013013815-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2013-01-31 — — WO disclosed
US-20130029962-A1 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2013-01-31 — — US disclosed
US-20130029962-A1 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2013-01-31 — — US disclosed
WO-2013013815-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2013-01-31 — — WO disclosed
WO-2011159760-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE VITAE PHARMACEUTICALS, INC. (US) 2011-12-22 — — WO disclosed
WO-2011159760-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE VITAE PHARMACEUTICALS, INC. (US) 2011-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130244993-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE CYP11B1, CYP11B2, HSD3B1 GBA1 1093/4885ALDH1A1 228/4885KDM4E 2449/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 GBA1 113/4885ALDH1A1 2427/4885KDM4E 4774/4885
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 GBA1 4035/4885ALDH1A1 3576/4885KDM4E 1997/4885
US-11912721-B2 Fused pentacyclic imidazole derivatives TNF, NFKBIA, TNFRSF1A GBA1 768/4885ALDH1A1 367/4885KDM4E 4607/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR GBA1 103/4885ALDH1A1 2642/4885KDM4E 4796/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 GBA1 113/4885ALDH1A1 2427/4885KDM4E 4774/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 GBA1 113/4885ALDH1A1 2427/4885KDM4E 4774/4885
US-20130029962-A1 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands TRPV1, GPR17, TRPV3 GBA1 3857/4885ALDH1A1 3441/4885KDM4E 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.